Other Events ·
AstraZeneca reported positive high-level results from the planned interim analysis of the DeLLphi-305 Phase III trial…
AZNAstrazeneca PLC
AstraZeneca reported positive high-level results from the planned interim analysis of the DeLLphi-305 Phase III trial, demonstrating that Imfinzi (durvalumab) plus Amgen's Imdelltra (tarlatamab) significantly improved overall survival and progression-free survival versus Imfinzi alone as first-line maintenance treatment for extensive-stage small cell lung cancer. The trial randomized 563 patients who had not progressed following induction therapy, establishing the combination as a new standard of care with no new safety signals identified. These findings reinforce Imfinzi's role in reshaping lung cancer treatment and will be shared with global regulatory authorities. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals.